Status:
TERMINATED
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Ov...
Detailed Description
This study was terminated on March 8, 2010 due to an analysis by an independent Data Safety Monitoring Committee (DSMC) indicating that the addition of CP-751,871 \[figitumumab\] to erlotinib \[Tarcev...
Eligibility Criteria
Inclusion
- Non small cell lung cancer with a primary histology of squamous cell, large cell or adenosquamous carcinoma. At least 1 measurable lesion, as defined by RECIST.
Exclusion
- Primary NSCLC adenocarcinoma and its subtypes or unknown/unspecified histology.
- Prior Erlotinib therapy.
- Prior anti IGF IR based investigational therapy.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
583 Patients enrolled
Trial Details
Trial ID
NCT00673049
Start Date
May 1 2008
End Date
April 1 2012
Last Update
July 24 2013
Active Locations (175)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Fort Smith, Arkansas, United States, 72903
2
Pfizer Investigational Site
Hot Springs, Arkansas, United States, 71913
3
Pfizer Investigational Site
Lakeport, California, United States, 95453
4
Pfizer Investigational Site
Orange, California, United States, 92868-3298